Free shipping on all orders over $ 500


Cat. No. M21184
Soticlestat Structure

TAK-935; OV935

Size Price Availability
5mg USD 220  USD220 Out of stock
10mg USD 375  USD375 Out of stock
25mg USD 700  USD700 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, orally active inhibitor of cholesterol 24-hydroxylase (CH24H), which is used in the study of epilepsy syndromes.

Chemical Information
Molecular Weight 373.45
Formula C23H23N3O2
CAS Number 1429505-03-2
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.


[1] Cecil D Hahn, et al. Epilepsia. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)

[2] Toshiya Nishi, et al. Epilepsia. Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor

[3] Nicole A Hawkins, et al. Epilepsia. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice

[4] Adam Strzelczyk, et al. CNS Drugs. Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

[5] Toshiya Nishi, et al. Sci Rep. Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice

Related Cytochrome P450 (e.g. CYP17) Products

TP0472993 is a novel, orally active, selective inhibitor of 20-hydroxyeicosatetraenoic acid (20-HETE) synthesis that inhibits the production of 20-HETE, thereby reducing the ERK1/2 and STAT3 signaling pathways, and ultimately inhibiting the progression of renal fibrosis. It can be used in studies related to chronic kidney disease (CKD).

Kushenol M

Kushenol M is a flavonoid from Sophora flavescens. Kushenol M is a cytochrome P450 (CYP) inhibitor, with IC50 values of 1.29 μM for CYP3A4 in human liver microsomes.


Peucedanol is a non-competitive inhibitor of CYP3A4 with a Ki value of 4.07 μM and a competitive inhibitor of CYP1A2 and CYP2D6 with Ki values of 3.39 μM and 6.77 μM, respectively.


Methysticin is a major kavalactone in kava extract to induce CYP1A1.


Isoglycycoumarin is a flavonoid isolated from the roots of Glycyrrhiza uralensis. Isoglycycoumarin is a highly selective probe for human cytochrome P450 2A6 (CYP2A6).

Abmole Inhibitor Catalog

Keywords: Soticlestat, TAK-935; OV935 supplier, Cytochrome P450 (e.g. CYP17), inhibitors, activators

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.